Where Will Rocket Lab Stock Be by This Time Next Year?

Rocket Lab shares have fallen 57% from their late-May peak amid potential Neutron delays into 2027 and its planned $8 billion acquisition of Iridium, a substantial transaction relative to Rocket Lab's $38 billion market value. Despite ongoing unprofitability, the company has a $2.36 billion backlog versus $434 million in first-half 2026 reportable business, supported by customers including NASA, the U.S. Department of Defense and Viasat. Analysts rate RKLB a strong buy with a $113.76 12-month target, implying more than 70% upside, though execution and launch-development risks remain material.

Analysis

The central valuation issue is not launch cadence but capital intensity. A satellite-services acquisition could make RKLB’s revenue mix more recurring and defense-relevant, but an $8B transaction would likely require substantial stock issuance, leverage, or both; each path limits the upside from multiple expansion unless acquired EBITDA, financing terms, and regulatory approvals are demonstrably favorable. Until a definitive proxy provides those terms, analyst price targets are not a usable valuation anchor because they may not reflect dilution or a higher cost of capital.

Near term (days to 1-3 months), RKLB remains vulnerable to estimate cuts tied to a revised Neutron schedule and transaction-financing disclosure. Over 6-18 months, the more important catalyst is whether space-systems gross margin and government contract conversion can fund development without repeated equity raises; that would justify treating RKLB as a defense/space-infrastructure platform rather than a binary launch bet. A medium-lift delay also creates a relative opportunity for public satellite communications names with existing capacity, while a successful integration would strengthen RKLB’s bargaining power against component suppliers and vertically integrated competitors.

Consensus appears to be treating the selloff as an execution discount that backlog alone can cure. The contrarian concern is that backlog is not equivalent to cash flow: cancellation rights, milestone timing, fixed-price contract exposure, and working-capital demands matter more than headline order value. The bullish thesis is falsified by another material schedule slip, negative space-systems margin progression, or acquisition funding that drives pro forma net leverage above management’s stated comfort range; it is validated by disclosed accretion, committed launch customers, and stable cash burn despite integration costs.

Key Decisions for Investors

• Do not initiate a core RKLB long before definitive IRDM transaction terms and financing are released; place a buy watch on a pro forma valuation that still offers at least 25% upside after assuming 15-20% equity dilution. Reassess within 1-3 months of the proxy/financing filing.
• For high-risk tactical exposure, use a small RKLB call spread 6-9 months out rather than common stock, entered only after financing clarity: buy an at-the-money call and sell a strike 30-40% higher. This caps downside to premium while targeting a rerating from regulatory clearance or credible integration guidance.
• Consider a 3-6 month relative-value hedge: long IRDM / short RKLB in equal dollar amounts if the deal spread widens and RKLB has not secured committed financing. IRDM is supported by takeout-value mechanics, while RKLB bears dilution and execution risk; exit if the transaction is repriced, terminated, or financing is fully committed on favorable terms.
• Track VSAT as a read-through and potential relative long against RKLB around launch-delay disclosures. A confirmed RKLB medium-lift slippage should temporarily improve the value of incumbent satellite-network capacity; close the trade if RKLB announces firm Neutron milestones plus customer deposits or VSAT’s liquidity outlook deteriorates.